Aims: Myeloperoxidase activity can contribute to impaired vascular endothelial function and fibrosis in chronic inflammation-related cardiovascular disease. Here, we investigated the safety, tolerability and pharmacokinetics of the myeloperoxidase inhibitor, AZD4831.
Myeloperoxidase is an emerging therapeutic target in the development of new treatments for inflammation-related cardiovascular diseases. The principal function of myeloperoxidase is to mediate the oxidative killing of microbes in neutrophil phagolysosomes.
Some myeloperoxidase is, however, also released into the extracellular space, where its oxidative activity can contribute to tissue damage, fibrosis and impaired vascular endothelial function. [1] [2] [3] Extracellular myeloperoxidase binds with high avidity to negatively charged proteoglycans on the surface of vascular endothelial cells. 4, 5 This blood vessel-associated myeloperoxidase can locally deplete nitric oxide, inhibit vasodilation and mediate the recruitment of circulating leukocytes, with resulting amplification of local inflammation. 2, 6 Long-term elevation of myeloperoxidase activity may be involved in the development of cardiovascular disease in humans.
Leukocyte numbers and blood levels of myeloperoxidase are elevated in patients with coronary artery disease. 7 In patients with acute coronary syndromes or chronic heart failure, high plasma levels of myeloperoxidase are associated with advanced disease and an increased risk of future cardiovascular events. [8] [9] [10] Furthermore, increased incidence of atrial fibrillation is associated with elevated plasma levels of myeloperoxidase in patients with pacemakers. 1 Conversely, individuals with low myeloperoxidase levels are resistant to inflammation-induced endothelial dysfunction. 11 Inhibition of myeloperoxidase is associated with reduced plasma concentrations of uric acid, 12 a marker of oxidative stress and chronic inflammation. Uric acid levels are elevated in people with cardiovascular disease, and high levels are associated with vascular dysfunction and cardiovascular mortality. [13] [14] [15] Inhibiting myeloperoxidase may therefore provide therapeutic benefit in patients with cardiovascular diseases, by limiting impairment of vascular function and the subsequent development of fibrosis.
The canonical enzymatic activity of myeloperoxidase is the oxidation of chloride ions (Cl − ) in the presence of hydrogen peroxide (H 2 O 2 )
to produce hypochlorous acid (HOCl), which mediates the bactericidal effect. 16 Myeloperoxidase can also oxidize a range of other physiological substrates, 17 including tyrosine, 18 Here, we report the results from a first-in-human, phase I study of the safety, tolerability and pharmacokinetics of single ascending doses of AZD4831 in healthy volunteers. The study also assessed serum uric acid levels as an exploratory pharmacodynamic outcome.
| METHODS

| Overview and objectives
This was a randomized, single-blind, placebo-controlled, phase I, firstin-human study of the safety and tolerability of the myeloperoxidase inhibitor, AZD4831, in healthy male volunteers (ClinicalTrials.gov identifier: NCT02712372). The study was originally designed to include a single ascending dose period and a multiple ascending dose period.
Based on results and experience from the single ascending dose period, the multiple ascending dose period was cancelled.
Multiple ascending doses in healthy volunteers were later tested in a separate study (ClinicalTrials.gov identifier: NCT03136991; to be reported elsewhere).
The study included two parts. In part A, sequential cohorts of participants received a single oral dose of AZD4831 or placebo under fasting conditions. In part B, one cohort of participants who had already received AZD4831 in part A then received a second single oral dose of AZD4831 under fed conditions.
The primary objective of the study was to evaluate the safety and tolerability of AZD4831 in healthy volunteers. Secondary objectives were to characterize the pharmacokinetics of AZD4831 and to investigate the effect of food intake on the pharmacokinetics. Evaluation of the pharmacodynamics of AZD4831 by assessment of uric acid concentration in serum was an exploratory objective.
What is already known about this subject
• Myeloperoxidase activity in blood vessels can contribute to impaired vascular endothelial function and fibrosis.
• Elevated plasma myeloperoxidase levels are associated with increased cardiovascular morbidity and mortality in humans.
• Vessel-associated myeloperoxidase is a promising therapeutic target for the treatment of chronic inflammation-related cardiovascular disease.
What this study adds
• Single 5-405 mg doses of the orally administered myeloperoxidase inhibitor, AZD4831, showed rapid and dose-dependent systemic absorption in healthy men.
• AZD4831 was well tolerated, with moderate maculopapular rash as the only identified risk.
• AZD4831 administration decreased serum uric acid concentrations; these findings support the further clinical development of AZD4831. Practice. An independent ethics committee and institutional review board reviewed and approved the study protocol and its amendments.
| Conduct and ethics
All participants freely gave their written informed consent before starting the study. The study was registered with ClinicalTrials.gov (identifier: NCT02712372). ). 
| Participants
| Part B: open-label, food effect evaluation stage
| Urinary pharmacokinetics
Urine was collected for pharmacokinetic analyses before dosing (spot sample) and 0-3, 3-6, 6-9, 
| Statistical methods
Sample size for this exploratory study was based on previous experience with similar studies, rather than on formal statistical considerations. The safety analysis set included all participants who received AZD4831 or placebo with available postdose safety data. The pharmacokinetic analysis set included all participants in the safety analysis set with evaluable pharmacokinetic data and no major protocol deviations. Analyses were performed using Statistical Analysis System (SAS) software, version 9.4. Descriptive statistics were not presented if there were fewer than 3 values available.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 25 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18.
26,27
3 | RESULTS
| Participant disposition and baseline characteristics
Forty white men, aged 19-50 years, were enrolled and randomized.
The participants' mean BMI was 24.3 kg m −2 (standard deviation
[SD] 2.3) in the AZD4831 group and 24.3 kg m −2 (SD 2.2) in the placebo group. All participants received one dose of AZD4831 (n = 30) or placebo (n = 10) and completed part A. All participants were included in the safety analyses and all participants who received AZD4831 were included in pharmacokinetic analyses. Four of the six participants in the AZD4831 45 mg cohort in part A also participated in part B of the study and all four completed part B. Two participants were withdrawn from the study before part B, with participant decision (n = 1) and noncompliance with the study protocol (n = 1)
as the reasons for discontinuation.
| Pharmacokinetic analyses 3.2.1 | Plasma pharmacokinetics of AZD4831 under fasted conditions
AZD4831 distributed rapidly into plasma, reaching C max at 0.51-1.00 hours after a single oral dose ( Figure 1A ; 
| Effect of food intake on plasma pharmacokinetics of AZD4831
Administration of AZD4831 45 mg immediately after a high-fat, high-calorie meal led to a reduced rate of absorption compared with administration under fasting conditions ( Figure 1B ; Table 1 ). C max was reduced by 44% and t max was delayed by 2.5 hours. Food intake before dosing also slightly reduced AUC 0-∞ and slightly increased t 1/2λz (Table 1) .
| Urinary pharmacokinetics of AZD4831 under fasted conditions
The mean fraction of the AZD4831 dose excreted in urine over the Data are geometric mean (coefficient of variation), except for t max , which is shown as median (range). a n = 4.
λz, elimination rate constant; AUC 0-∞ , area under the plasma concentration-time curve from time zero extrapolated to infinity; AUC 0-t , area under the plasma concentration-time curve from time zero to time of last quantifiable analyte concentration; CL/F, apparent clearance; CL R , renal clearance; C max , observed maximum concentration; NE, not estimated; t 1/2λz , half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve; t max , time to reach maximum observed concentration; V Z /F, apparent volume of distribution. from the study before part B (with protocol noncompliance as the reason for discontinuation). AEs of maculopapular rash had a duration of 5-9 days and were reported 7-9 days after dosing; all had resolved by the end of the study.
| Laboratory and physical assessments
There were no systemic or dose-related changes in clinical chemistry (Table S1 ), haematology (Table S2) (Table S1 ). There were no clinically significant changes in vital signs or electrocardiography parameters during the study (Table S3) . Uric acid generation from purines is augmented by tissue hypoxia, and has been reported to be increased in the cardiac tissue of patients with heart failure. 13 This suggests an alternative or additional potential mechanism for reduced uric acid levels following AZD4831 inhibition of myeloperoxidase. A reduction in vascular myeloperoxidase activity could lead to increased nitric oxide bioavailability, which may improve vascular endothelial function and tissue perfusion, 11 with a resulting decrease in hypoxia-dependent uric acid generation from purines. Whether this mechanism contributed to the reduced uric acid levels seen in the current study in healthy volunteers is unclear, as is whether greater effects on uric acid would been seen in patients with hypoxia. The present study did not aim to investigate the mechanisms underlying the effects of AZD4831 in the exploratory pharmacodynamic assessments. The phase I multiple ascending dose study of AZD4831 in healthy volunteers (ClinicalTrials.gov identifier: NCT03136991) will provide additional data on uric acid levels over a 10-day treatment period. Future studies will aim to investigate the mechanism of AZD4831-mediated uric acid reduction by comparing functional and biochemical outcomes. A planned study in patients referred for cardiac catheterization (ClinicalTrials.gov identifier: NCT03611153) will assess the effect of AZD4831 on haemodynamics, exercise capacity and endothelial function.
The present study provided clear pharmacokinetic parameters and the first safety data for AZD4831 in healthy human volunteers. The following aspects of the study should be borne in mind when interpreting the results. The number of participants in the study was the smallest required to meet study objectives without unnecessarily placing healthy volunteers at potential risk from an investigational drug. The study design did not anticipate the long half-life of AZD4831, which resulted in amendment of the sampling schedule after the first cohort, to include additional time points. Finally, the study was not designed to assess the pharmacodynamics of AZD4831, except as an exploratory objective.
This first study of AZD4831 in humans revealed that oral administration led to rapid and dose-dependent absorption, with generally low interparticipant variability in systemic exposure. AEs were mild or moderate, with maculopapular rash identified for monitoring in future studies.
These findings support the further clinical development of AZD4831 as a treatment for chronic, inflammatory cardiovascular diseases.
